Search

OBJECTIVE: To probe into the efficacy of olanzapine combined with Naoxintong capsules in the treatment of schizophrenia and its effects on serum α-synuclein and melatonin levels. METHODS: Totally 124 patients with schizophrenia admitted into the hospital from Mar. 2021 to May 2023 were extracted to be divided into the control group and observation group via the random number table method, with 62 cases in each group. The control group received olanzapine as their treatment, while the observation group was given Naoxintong capsules on the basis of the control group for a duration of 8 weeks. The clinical efficacy, state of mind, quality of life, function of cognition, metabolism of glucose, serum α-synuclein and melatonin levels of two groups were compared. RESULTS: The total effective rate of the observation group was significantly higher than that of the control group [85. 48% (53 / 62) vs. 69. 35% (43 / 62)], the difference was statistically significant (P<0. 05). After treatment, the positive symptoms, negative symptoms, psychopathological manifestations and the total scores of positive and negative symptom scales in the observation group were significantly lower than those in the control group, the psychosocial scores, symptom and side effect scores, exercise and energy scores were lower than those in the control group, and the neuropsychological status scale scores were significantly higher than those in the control group, with statistically significant differences (P<0. 05). The levels of fasting blood glucose and 2 h postprandial blood glucose after treatment in the observation group were lower than those in control group, and the α-synuclein and melatonin levels were higher than those in control group, with statistically significant differences ( P < 0. 05 ). The incidence of adverse drug reactions in observation group and control group was respectively 4. 84% ( 3 / 62) and 6. 45% ( 4 / 62), with no statistically significant difference (P>0. 05). CONCLUSIONS: Olanzapine combined with Naoxintong capsules can significantly increase the efficacy of patients with schizophrenia, restore state of mind, quality of life, function of cognition and metabolism of glucose, and improve serum α-synapse protein and melatonin levels, with few adverse drug reactions. [ABSTRACT FROM AUTHOR]

To study the reference range of olanzapine concentration in the treatment of schizophrenia. METHODS: According to inclusion and exclusion criteria, age, gender, daily dose, administration time, daily administration frequency, drug combination, scale score and adverse drug reactions of inpatients from Xi’ an Mental Health Center from Jun. 2016 to Mar. 2022 were collected. The correlation between olanzapine concentration and collection index was analyzed. The effective reference range of olanzapine concentration was determined, and the warning value was determined combined with the incidence of adverse drug reactions. RESULTS: There were statistically significant differences in olanzapine concentration among patients with different ages and daily doses (F= 1. 138, F= 1. 322; P<0. 05), the olanzapine concentration of male patients was significantly lower than that of female patients [(39. 29±24. 48)ng / mL vs. (49. 93±26. 92) ng / mL, Kolmogorov-Smirnov test = 0. 201 4, P<0. 01)]. Olanzapine concentration was positively correlated with daily dose ratio (r = 0. 225 4, t = 36. 36, P<0. 01), adverse drug reactions ( t = 2. 013, P<0. 05). According to the principle of maximum detection rate value, 30 ng / mL was the lower limit of the reference range (≥ threshold detection rate was 8. 561%), 90 ng / mL was the upper limit of the reference range ( < threshold detection rate was 2. 022%), 130 ng / mL was the alert value ( adverse drug reaction rate ≥70%). The detection rate of 15 ng / mL was better than 90 ng / mL ( threshold detection rate: 4. 187% vs. 2. 022%). CONCLUSIONS: There are individual differences in patients using olanzapine with different gender, age and daily dose, and the incidence of adverse drug reactions is high, so that olanzapine concentration should be routinely monitored clinically. It is recommended that 15 to 90 ng / mL be used as the reference range and 130 ng / mL as the alert value. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the effects of fluoxetine hydrochloride combined with olanzapine on serum S100β and brain-derived neurotrophic factor ( BDNF) in elderly patients with depressive episode and intractable hypochondriasis. METHODS: Totally 105 patients with depressive episode and intractable hypochondriasis admitted into Xianyang Hospital of Yan’an University from Dec. 2018 to Jun. 2020 were extracted to be divided into the observation group (55 cases) and the control group (50 cases) via random number table. The control group was treated with fluoxetine hydrochloride capsules, while the observation group received fluoxetine hydrochloride capsules combined with olanzapine tablets. The levels of S100β and BDNF were detected before treatment and after treatment of 8 weeks, depressive symptoms [ Hamilton depression scale ( HAMD)], sleep quality [ Pittsburgh sleep quality index, PSQI) and quality of life [ World Health Organization quality of life (WHOQOL-BREF)] were evaluated. The incidence of adverse drug reactions were recorded. RESULTS: After treatment, the level of S100β in the observation group was significantly lower than that in the control group, the level of BDNF was significantly higher than that in the control group, and the difference was statistically significant (P< 0. 05). After treatment, Hamilton scale score and PSQI score in the observation group were significantly lower than those in the control group, WHOQOL-BREF score and total score were significantly higher than those in the control group, with statistically significant difference (P<0. 05). The incidence of adverse drug reactions in the observation group and the control group was respectively 10. 91% (6/55) and 14. 00% ( 7/50), the difference was not statistically significant (P>0. 05). CONCLUSIONS: The clinical efficacy of Fluoxetine hydrochloride combined with olanzapine in the treatment of elderly patients with depressive episode and intractable hypochondriasis is significant, which can effectively improve the level of BDNF and reduce the level of S100β. [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)